Skip to main content

Fiscal Wizard · Single-issue tearsheet

SNTI / Jun 21, 2026 Run #7302

SNTI

Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Composite verdict

F 7.0 / 100
Bearish setup · Trend Following 10 drivers · 8 gates blocking
  • Rate of Change
  • Vortex Signal
  • Engulfing
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 488th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 24 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

14.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Greenblatt ROC 0
P/B 75
Free Cash Flow Yield 0
FCF Margin 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, Vortex Signal, Engulfing); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 4
Vortex Signal 9
Engulfing 12

Risk Gates

8 blocking 2 caution

8 guards active, 17 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SNTI.